JP2022525339A5 - - Google Patents

Info

Publication number
JP2022525339A5
JP2022525339A5 JP2021555384A JP2021555384A JP2022525339A5 JP 2022525339 A5 JP2022525339 A5 JP 2022525339A5 JP 2021555384 A JP2021555384 A JP 2021555384A JP 2021555384 A JP2021555384 A JP 2021555384A JP 2022525339 A5 JP2022525339 A5 JP 2022525339A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
coa
acidemia
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022760 external-priority patent/WO2020186216A1/en
Publication of JP2022525339A publication Critical patent/JP2022525339A/ja
Publication of JP2022525339A5 publication Critical patent/JP2022525339A5/ja
Pending legal-status Critical Current

Links

JP2021555384A 2019-03-14 2020-03-13 有機酸血症の治療方法 Pending JP2022525339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818372P 2019-03-14 2019-03-14
US62/818,372 2019-03-14
PCT/US2020/022760 WO2020186216A1 (en) 2019-03-14 2020-03-13 Methods of treating organic acidemias

Publications (2)

Publication Number Publication Date
JP2022525339A JP2022525339A (ja) 2022-05-12
JP2022525339A5 true JP2022525339A5 (https=) 2023-03-24

Family

ID=72426817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555384A Pending JP2022525339A (ja) 2019-03-14 2020-03-13 有機酸血症の治療方法

Country Status (11)

Country Link
US (1) US20220142955A1 (https=)
EP (1) EP3937922A4 (https=)
JP (1) JP2022525339A (https=)
KR (1) KR20210139274A (https=)
CN (1) CN113557014A (https=)
AU (1) AU2020236023A1 (https=)
BR (1) BR112021018036A2 (https=)
CA (1) CA3133260A1 (https=)
EA (1) EA202192497A1 (https=)
IL (1) IL285822A (https=)
WO (1) WO2020186216A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216848A1 (en) * 2021-04-06 2022-10-13 Hemoshear Therapeutics, Inc. Methods of treating methylmalonic acidemia and propionic acidemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249706B (it) * 1991-09-18 1995-03-09 Sigma Tau Ind Farmaceuti Uso di l-carnitina nella gravidanza a rischio.
AU3889197A (en) * 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
US20050027006A1 (en) * 2003-07-28 2005-02-03 Reuben Matalon Methods and materials for treating conditions associated with metabolic disorders
WO2011072086A1 (en) * 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20120289476A1 (en) * 2009-12-11 2012-11-15 Jay Allan Barth Methods for treating methylmalonic acidemia
US9018176B2 (en) * 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
ES2795798T3 (es) * 2011-07-06 2020-11-24 Ptc Therapeutics Inc Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas
EP2877444B1 (en) * 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20180064154A9 (en) * 2015-09-01 2018-03-08 D. Holmes Morton Management of propionate metabolism disorders
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
WO2017139697A1 (en) * 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2017184583A1 (en) * 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism

Similar Documents

Publication Publication Date Title
JP7585037B2 (ja) 非ラセミ体のベータ－ヒドロキシブチレート化合物及びｒ－エナンチオマー富化組成物並びに使用方法
US10596128B2 (en) Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US12329734B2 (en) Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10292952B2 (en) Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
KR102499654B1 (ko) 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
US12186297B2 (en) Compositions and methods for increasing lean-to-fat mass ratio
KR101601987B1 (ko) 신장 보호제로서 중쇄 길이 지방산 및 글리세라이드
CN112351774A (zh) 用于β-羟基丁酸和乙酰乙酸的酮堆叠的组合物和方法
US20190262293A1 (en) Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the r-enantiomer and methods of use
MX348225B (es) Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
WO2010038796A1 (ja) Ｃ型肝炎治療剤
JP2013521310A5 (https=)
JP2013512966A5 (https=)
RU2017112308A (ru) Композиции и способы для лечения бессонницы
JP2017503761A5 (https=)
JP2022525339A5 (https=)
RU2019111096A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP2017519028A5 (https=)
JP6100510B2 (ja) 抗感冒剤
US20250090485A1 (en) Compositions containing hmb and ketone bodies and methods for increasing lean-to-fat mass ratio
JP2022520204A (ja) Ｓ－ベータ－ヒドロキシブチレート化合物およびｓ－エナンチオマー富化組成物
US20090012170A1 (en) Treatment of symptoms of motor dysfunction
US20250381162A1 (en) S-beta-hydroxybutyrate esters for improving metabolic function
US20260000633A1 (en) Use of s-beta-hydroxybutyrate compounds to improve heart function in a human
CN104869988B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在治疗动脉粥样硬化中的用途